CAS Registry Number is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-04-07. Numbers and descriptions here follow the published literature rather than marketing material.
Identity and purity are usually assessed with reverse-phase high-performance liquid chromatography and mass spectrometry. These methods can separate related impurities and confirm molecular mass, but they do not by themselves establish biological activity. Certificate of analysis documents may report purity as a percentage by area, yet the exact meaning can vary between laboratories. Independent testing can check for residual solvents, counterions, or microbial contamination when relevant. For research use, matching analytical records to a specific lot helps trace experimental variability.
Dihexa occupies an uncertain regulatory space in many countries. It is not generally listed as an approved therapeutic, and some jurisdictions may treat it as a research chemical, a compounded substance, or an unapproved new drug depending on claims and distribution. Importation can be restricted, and suppliers may require documentation that the material is for laboratory research only. Quality and labeling vary, so buyers should request analytical data, verify lot numbers, and understand local rules. These factors make sourcing and compliance part of the practical context around dihexa.
Lyophilized dihexa is typically stored as a dry powder at or below minus twenty degrees Celsius. Cooler temperatures slow degradation, and desiccant protection limits moisture uptake. Repeated temperature cycling can accelerate breakdown, so aliquoting before storage is common in laboratory practice. Solutions are generally less stable than dry powder and are often kept cold, protected from light, and used within a defined period. Specific stability data for dihexa are limited, and handling recommendations often follow general peptide guidelines rather than compound-specific studies.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C or lower | For lyophilized powder; avoid repeated freeze-thaw. |
| Appearance | White to off-white powder | Common for lyophilized peptides. |
| Solubility | Soluble in water and aqueous buffers | Limited solubility in nonpolar solvents. |
| Typical analytical method | Reverse-phase HPLC and mass spectrometry | Used for purity and identity checks. |
| Typical purity specification | 95% or greater by HPLC area | Supplier values vary; not a biological potency measure. |
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
=== Lethality === The mean lethal dose in rats (i.p.) for ATR is 143 mg/kg and for CATR is 2.9 mg/kg. This lethal dose of ATR takes approximately 150–180 minutes after injection until acute tubular necrosis occurred. This lethal dose varies across species and method of exposure. For example, the mean lethal dose of ATR in rats (s.c.) is 155 mg/kg. Published mean lethal doses of ATR in other species includes 250 mg/kg (s.c.) for rabbit, 200 mg/kg (i.p.) for guinea pig, and 15 mg/kg (i.v.) for dog.
=== Nanoparticle-based Controlled-Release === The use of nanotechnology into drug delivery has opened the door to new possibilities, particularly with the development of nanoparticle-based controlled-release systems. These systems are designed to deliver drugs more precisely and over longer periods of time helping with targeted sites and therapeutic effects. Tiny carriers, such as liposomes, dendrimers, and polymeric nanoparticles, can hold medication and release them at controlled rates. Some are even engineered to respond to specific conditions in the body. For instance, acidic microenvironment commonly found in tumor tissues can be used to trigger drug release at the site needed. This targeted approach helps minimize side effects by limiting exposure to the rest the body. Thus, making treatment more effective. Recent studies have shown the effectiveness of smart nanoparticles that respond to biological cues, such as pH or redox conditions, thereby delivering drugs more precisely to tumor sites. For instance, pH-sensitive nanoparticles take advantage of the lower pH in tumor cells to release the drugs, which boost effectiveness while protecting healthy cells. Additionally, the use of biocompatible materials and switching the nanoparticle surfaces have improved their accuracy and release of delivery systems. Advances in design have also made it possible to create multi-functional nanoparticles that are capable of handling tough challenges like multi-drug resistance in cancer.
== Hair Testing History == 1858: Hoppe-Seyler publishes report finding arsenic in the hair in an 11-year old buried body. 1978: Dr. Werner Baumgartner, PhD develops a radioimmunological(RIA)method for detecting drug use from hair specimens. 1987: Psychemedics begins offering services commercially
=== Ukraine === The epidemic of HIV/AIDS in Ukraine is quickly growing and was the reason for research into opioid agonist therapies (OAT) in the country as a means to curb the spread of HIV. Ukraine has the highest rate of HIV in Europe at 1.2% and most of the spread of HIV in Ukraine is primarily through people who inject drugs and secondarily through these drug users sexual partners. In 2016, opioid agonist therapies were only being given to 2.7% of the 346,000 people who inject drugs in Ukraine. OAT utilized Buprenorphine starting in 2004 and Methadone in 2008. However, due to the cost of OAT, government regulation prohibits the number of patients that can receive such therapies at a time, meaning a new patient can enter only after another has left. From 2010 to 2013 this number patients remained at a ceiling of roughly 9,000 patients throughout the country. As of 2016 OAT for these 9,000 patients is being administered only by narcologists at 174 licensed treatment centers.
It found ceftolozane/tazobactam to be at least as effective as meropenem: the infection had resolved in 54% of participants (197 out of 362) after 7 to 14 days of treatment with ceftolozane/tazobactam compared with 53% of participants (194 out of 362) on meropenem.
Sources: en.wikipedia.org
On April 15, 2026, Secretary Hegseth quoted a prayer based on lines from the 1994 film Pulp Fiction, part of which is from Ezekiel 25:17, during a Pentagon prayer session led by the secretary. The prayer had reportedly been used by the search and rescue team that saved two downed airmen in Iran earlier in April.
Morgan's athletic teams are known as the Bears, and they compete in the Mid-Eastern Athletic Conference (MEAC). Between 1926 and 1928, a young Charles Drew served as Athletic Director. During this time he made great improvements in the school's teams' records. From the 1930s through 1960s, led by coach and then athletic director Edward P. Hurt, Morgan's athletic teams were legendary. More than thirty of its football players were drafted by and played in the NFL and many of its track athletes competed internationally and received world-class status. By the late 1960s most white colleges and universities ended their segregation against black high school students and many top black high school students and athletes started matriculating to schools from which they had previously been barred. While achieving a national goal of desegregation, integration depleted the athletic strength of schools like Morgan State and Grambling State University. For example, the annual contest between Morgan State and Grambling played in New York City in the late 1960s drew more than 60,000 fans. Morgan State's rivals are the Howard University Bison (the matchup is often called the Battle of the Beltway) and the Coppin State Eagles.
== History == Clocinnamox was first described in the scientific literature by 1992. Methoclocinnamox, which is metabolically converted into clocinnamox and is a μ-opioid receptor partial agonist, was first described by 1995. Methocinnamox was first described in 2000.
A vaccine vial monitor (VVM) is a time temperature indicator put on vials containing vaccines which gives a visual indication of whether the vaccine has been kept at a temperature which preserves its potency. A VVM slowly changes color as it is exposed to heat, accelerating as the environment gets hotter. The VVM helps healthcare workers determine a vaccine left out of the cold chain is still effective. Many of vaccines can survive days even at a scorching 40 °C (104 °F), but without a VVM there is no way to tell whether a vaccine has been destroyed by spending too many days sitting hot. The VVM provides that information and allows this type of operation (controlled temperature chain) to be safely conducted. This is especially important when delivering vaccines to developing countries where the cold chain is difficult to preserve.
Sources: en.wikipedia.org
The lyophilized powder is commonly kept at -20 °C or lower, protected from moisture and light. Solutions may require colder storage and should avoid repeated freeze-thaw cycles. General peptide stability practices apply.
Reverse-phase HPLC can estimate purity, while mass spectrometry helps confirm molecular mass. These methods do not prove biological effects. Lot-specific certificates may provide additional data.
It is not an approved medicine in major jurisdictions. Depending on the country and marketing claims, it may be treated as a research chemical or unapproved substance. Import and sale rules vary.
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.